285 related articles for article (PubMed ID: 29554088)
1. KCa3.1 ion channel: A novel therapeutic target for corneal fibrosis.
Anumanthan G; Gupta S; Fink MK; Hesemann NP; Bowles DK; McDaniel LM; Muhammad M; Mohan RR
PLoS One; 2018; 13(3):e0192145. PubMed ID: 29554088
[TBL] [Abstract][Full Text] [Related]
2. Blockade of the intermediate-conductance Ca(2+)-activated K+ channel inhibits the angiogenesis induced by epidermal growth factor in the treatment of corneal alkali burn.
Yang H; Li X; Ma J; Lv X; Zhao S; Lang W; Zhang Y
Exp Eye Res; 2013 May; 110():76-87. PubMed ID: 23482085
[TBL] [Abstract][Full Text] [Related]
3. Blockade of KCa3.1: A novel target to treat TGF-β1 induced conjunctival fibrosis.
Anumanthan G; Wilson PJ; Tripathi R; Hesemann NP; Mohan RR
Exp Eye Res; 2018 Feb; 167():140-144. PubMed ID: 29242028
[TBL] [Abstract][Full Text] [Related]
4. The KCa3.1 blocker TRAM-34 inhibits proliferation of fibroblasts in paraquat-induced pulmonary fibrosis.
Xie H; Lu J; Zhu Y; Meng X; Wang R
Toxicol Lett; 2018 Oct; 295():408-415. PubMed ID: 30036685
[TBL] [Abstract][Full Text] [Related]
5. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
[TBL] [Abstract][Full Text] [Related]
6. KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis.
Huang C; Shen S; Ma Q; Gill A; Pollock CA; Chen XM
Nephrol Dial Transplant; 2014 Feb; 29(2):313-24. PubMed ID: 24166472
[TBL] [Abstract][Full Text] [Related]
7. Altered K
Seo CH; Cui HS; Kim JB
Transl Res; 2021 Oct; 236():133-146. PubMed ID: 33905948
[TBL] [Abstract][Full Text] [Related]
8. Increased constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent.
Roach KM; Wulff H; Feghali-Bostwick C; Amrani Y; Bradding P
Respir Res; 2014 Dec; 15(1):155. PubMed ID: 25476248
[TBL] [Abstract][Full Text] [Related]
9. The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.
Hua X; Deuse T; Chen YJ; Wulff H; Stubbendorff M; Köhler R; Miura H; Länger F; Reichenspurner H; Robbins RC; Schrepfer S
Transplantation; 2013 Jan; 95(2):285-92. PubMed ID: 23325003
[TBL] [Abstract][Full Text] [Related]
10. Blockade of KCa3.1 Attenuates Left Ventricular Remodeling after Experimental Myocardial Infarction.
Ju CH; Wang XP; Gao CY; Zhang SX; Ma XH; Liu C
Cell Physiol Biochem; 2015; 36(4):1305-15. PubMed ID: 26160442
[TBL] [Abstract][Full Text] [Related]
11. Effects of Intermediate-Conductance Ca(2+)-Activated K(+) Channels on Human Endometrial Carcinoma Cells.
Zhang Y; Feng Y; Chen L; Zhu J
Cell Biochem Biophys; 2015 Jun; 72(2):515-25. PubMed ID: 25608633
[TBL] [Abstract][Full Text] [Related]
12. Role of
Gupta S; Martin LM; Sinha NR; Smith KE; Sinha PR; Dailey EM; Hesemann NP; Mohan RR
Mol Vis; 2020; 26():742-756. PubMed ID: 33273801
[TBL] [Abstract][Full Text] [Related]
13. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels.
Grgic I; Kiss E; Kaistha BP; Busch C; Kloss M; Sautter J; Müller A; Kaistha A; Schmidt C; Raman G; Wulff H; Strutz F; Gröne HJ; Köhler R; Hoyer J
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14518-23. PubMed ID: 19706538
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of KCa3.1 promotes human airway smooth muscle cell phenotypic modulation.
Yu ZH; Wang YX; Song Y; Lu HZ; Hou LN; Cui YY; Chen HZ
Pharmacol Res; 2013 Nov; 77():30-8. PubMed ID: 24055799
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a novel combination of TRAM-34 and ascorbic acid for the treatment of corneal fibrosis in vivo.
Fuchs AA; Balne PK; Giuliano EA; Sinha NR; Mohan RR
PLoS One; 2022; 17(1):e0262046. PubMed ID: 35007294
[TBL] [Abstract][Full Text] [Related]
16. Acetylcholine decreases formation of myofibroblasts and excessive extracellular matrix production in an in vitro human corneal fibrosis model.
Słoniecka M; Danielson P
J Cell Mol Med; 2020 Apr; 24(8):4850-4862. PubMed ID: 32176460
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of vascular calcification by block of intermediate conductance calcium-activated potassium channels with TRAM-34.
Freise C; Querfeld U
Pharmacol Res; 2014 Jul; 85():6-14. PubMed ID: 24813858
[TBL] [Abstract][Full Text] [Related]
18. The K+ channel KCa3.1 as a novel target for idiopathic pulmonary fibrosis.
Roach KM; Duffy SM; Coward W; Feghali-Bostwick C; Wulff H; Bradding P
PLoS One; 2013; 8(12):e85244. PubMed ID: 24392001
[TBL] [Abstract][Full Text] [Related]
19. Targeted inhibition of KCa3.1 channel attenuates airway inflammation and remodeling in allergic asthma.
Yu ZH; Xu JR; Wang YX; Xu GN; Xu ZP; Yang K; Wu DZ; Cui YY; Chen HZ
Am J Respir Cell Mol Biol; 2013 Jun; 48(6):685-93. PubMed ID: 23492185
[TBL] [Abstract][Full Text] [Related]
20. K
Bonito B; Sauter DR; Schwab A; Djamgoz MB; Novak I
Pflugers Arch; 2016 Nov; 468(11-12):1865-1875. PubMed ID: 27752766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
